인트론바이오

048530· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

₩2,665+2.30%

2026-08-04

Financials

Valuation Metrics

인트론바이오's Market Cap is ₩823B. At end of 2025 it was ₩1004B. Ranked #1400 of 2,436 in KR market (top 57%), #784 of 1,649 on KOSDAQ (top 48%), #154 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 66%) by Market Cap.

Investment Metrics(as of 2026-08-04)

Metric	Value	Rank
Size
Market Cap	82.33B KRW	KR#1,400/2,436 Sec#154/234
Revenue	6.44B KRW	KR#2,328/2,436 Sec#189/234
Net Income	-9.19B KRW	KR—/2,436 Sec—/234
Total Assets	70.68B KRW	KR#1,984/2,436 Sec#168/234
Net Assets	64.43B KRW	KR#1,704/2,436 Sec#145/234
Employees	70	KR#1,853/2,436 Sec#158/234
Value
P/B	1.28x	KR#1,663/2,436 Sec#117/234
P/S	12.79x	KR#2,297/2,436 Sec#168/234
Profitability
ROE	-14.26%	KR#1,976/2,436 Sec#155/234
ROA	-13.00%	KR#2,144/2,436 Sec#167/234
Op. Margin	-127.86%	KR#2,329/2,436 Sec#182/234
Revenue Growth	58.71%	KR#243/2,436 Sec#26/234
Financial Health
Debt Ratio	9.71%	KR#11/2,436 Sec#5/234
Total Debt	4.80B KRW	KR#1,791/2,436 Sec#171/234
Cash	25.06B KRW	KR#1,111/2,436 Sec#75/234
Current Ratio	9.81x	KR#104/2,436 Sec#28/234
Dividend
Div. Yield	11.92%	KR#18/2,436 Sec#2/234
Div. Growth	0.00%	KR—/2,436 Sec—/234
Performance
1Y Return	-31.49%	KR#1,746/2,436 Sec#149/234
1M Return	10.12%	KR#998/2,436 Sec#86/234
From 52W High	-61.98%	KR#1,853/2,436 Sec#152/234
1Y MDD	-64.96%	KR#1,693/2,436 Sec#143/234
Trading
Volume	67,218 shares	KR#908/2,436 Sec#80/234
Foreign Own.	2.27%	KR—/2,436 Sec—/234
Per Share
EPS	-272 KRW	KR—/2,436 Sec—/234
BPS	2,086 KRW	KR#2,006/2,436 Sec#165/234

Company Info

CEO 윤성준, 윤경원(각자대표)

Employees 70

Founded 1999

HQ 경기도 성남시, KR

Website www.intron.co.kr/

동사는 1999년 설립된 바이오 벤처기업으로 2011년 코스닥에 상장함. 신약파트는 박테리오파지 플랫폼 기술 기반 itLysin과 IMPA™ 기술분야로 신약개발을 추진하고, DR파트는 PCR 및 qPCR 기반 진단제품 개발·생산으로 수익을 창출함. 플랫폼으로 내성균 치료제, 백신개발, 면역치료제 영역까지 확장하며 'from SUPERBUG to IMMUNE' 개념으로 글로벌 기술을 선도하고 있음. 인트론바이오는 1999년에 설립되었으며 경기도 성남시에 본사를 두고 있습니다.